Shuhei Hakiri1, Takayuki Fukui2, Shunsuke Mori3, Koji Kawaguchi2, Shota Nakamura2, Naoki Ozeki2, Taketo Kato2, Masaki Goto2, Yasushi Yatabe4, Kohei Yokoi2. 1. Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: h-shuhei-1024@med.nagoya-u.ac.jp. 2. Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. 3. Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan. 4. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
Abstract
BACKGROUND: Programmed death ligand 1 (PD-L1) is reportedly expressed in various malignancies and is considered a prognostic factor. We attempted to reveal the usefulness of the PD-L1 expression as a prognostic factor in patients with thymoma. METHODS: Eighty-one patients with thymoma who underwent surgical resection between 2004 and 2015 were retrospectively reviewed. The PD-L1 expression was evaluated by immunohistochemistry and stratified by the proportion of positive tumor cells. Strong membranous reactivity of the PD-L1 antibody in 1% or more of tumor cells was considered "positive." The association between the PD-L1 expression and the clinicopathologic features was investigated. RESULTS: The PD-L1 expression was positive in 22 patients (27%) and negative in 59 patients (73%). The PD-L1 positivity was significantly associated with type B2 and B3 thymoma (p < 0.001) and stage III and IV disease (p = 0.048). In addition, PD-L1 positive tumors showed a significantly higher maximum standardized uptake value than PD-L1 negative tumors (p = 0.026). The 5-year disease-free survival rate was 82% in PD-L1 positive patients and 88% in PD-L1 negative patients, showing no significant difference (p = 0.57). Furthermore, PD-L1 positivity was not an independent prognostic factor for the disease-free survival on a Cox proportional hazards analysis (p = 0.59). CONCLUSIONS: A strong expression of PD-L1 in thymoma was significantly associated with type B2 and B3 and higher pathologic stages. In addition, PD-L1 positivity was associated with an increased maximum standardized uptake value of the tumor. However, patients with PD-L1 positive thymomas did not show a significantly worse prognosis than patients with PD-L1 negative tumors.
BACKGROUND:Programmed death ligand 1 (PD-L1) is reportedly expressed in various malignancies and is considered a prognostic factor. We attempted to reveal the usefulness of the PD-L1 expression as a prognostic factor in patients with thymoma. METHODS: Eighty-one patients with thymoma who underwent surgical resection between 2004 and 2015 were retrospectively reviewed. The PD-L1 expression was evaluated by immunohistochemistry and stratified by the proportion of positive tumor cells. Strong membranous reactivity of the PD-L1 antibody in 1% or more of tumor cells was considered "positive." The association between the PD-L1 expression and the clinicopathologic features was investigated. RESULTS: The PD-L1 expression was positive in 22 patients (27%) and negative in 59 patients (73%). The PD-L1 positivity was significantly associated with type B2 and B3thymoma (p < 0.001) and stage III and IV disease (p = 0.048). In addition, PD-L1 positive tumors showed a significantly higher maximum standardized uptake value than PD-L1 negative tumors (p = 0.026). The 5-year disease-free survival rate was 82% in PD-L1 positive patients and 88% in PD-L1 negative patients, showing no significant difference (p = 0.57). Furthermore, PD-L1 positivity was not an independent prognostic factor for the disease-free survival on a Cox proportional hazards analysis (p = 0.59). CONCLUSIONS: A strong expression of PD-L1 in thymoma was significantly associated with type B2 and B3 and higher pathologic stages. In addition, PD-L1 positivity was associated with an increased maximum standardized uptake value of the tumor. However, patients with PD-L1 positive thymomas did not show a significantly worse prognosis than patients with PD-L1 negative tumors.
Authors: Joon Seon Song; Deokhoon Kim; Ji Hyun Kwon; Hyeong Ryul Kim; Chang-Min Choi; Se Jin Jang Journal: Front Oncol Date: 2019-10-15 Impact factor: 6.244
Authors: Naixin Liang; Lei Liu; Cheng Huang; Hongsheng Liu; Chao Guo; Ji Li; Weiwei Wang; Nan Li; Rui Lin; Tao Wang; Lieming Ding; Li Mao; Shanqing Li Journal: Front Oncol Date: 2021-09-08 Impact factor: 6.244
Authors: Isabelle Rouquette; Estelle Taranchon-Clermont; Julia Gilhodes; Maria-Virginia Bluthgen; Romain Perallon; Lara Chalabreysse; Anne De Muret; Veronique Hofman; Alexander Marx; Marie Parrens; Veronique Secq; Vincent Thomas de Montpreville; Françoise Galateau-Salle; Pierre Brousset; Julie Milia; Nicolas Girard; Benjamin Besse; Thierry Jo Molina; Julien Mazières Journal: Biomark Res Date: 2019-12-04